Outcomes in COVID-19 ensitrelvir studies
0
0.5
1
1.5+
All studies
27%
2
255
Improvement, Studies, Patients
Relative Risk
Viral clearance
35%
2
249
RCTs
27%
2
255
Peer-reviewed
9%
1
227
Early
27%
2
255
Ensitrelvir for COVID-19
c19 early.org/en Mar 2023
Favors ensitrelvir
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Mukae (DB RCT)
45%
0.55 [0.37-0.81]
viral load
14 (n)
14 (n)
Improvement, RR [CI]
Treatment
Control
Mukae (DB RCT)
9%
0.91 [0.76-1.08]
improv.
116 (n)
111 (n)
Tau​2 ​ = 0.10, I​2 ​ = 81.4%, p = 0.21
Early treatment
27%
0.73 [0.45-1.19]
0/130
0/125
27% improvement
All studies
27%
0.73 [0.45-1.19]
0/130
0/125
27% improvement
2 ensitrelvir COVID-19 studies
c19 early.org/en Mar 2023
Tau​2 ​ = 0.10, I​2 ​ = 81.4%, p = 0.21
Effect extraction pre-specified (most serious outcome)
Favors ensitrelvir
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Mukae (DB RCT)
9%
0.91 [0.76-1.08]
improv.
116 (n)
111 (n)
Improvement, RR [CI]
Treatment
Control
Tau​2 ​ = 0.00, I​2 ​ = 0.0%, p = 0.28
Early treatment
9%
0.91 [0.76-1.08]
0/116
0/111
9% improvement
All studies
9%
0.91 [0.76-1.08]
0/116
0/111
9% improvement
1 ensitrelvir COVID-19 recovery result
c19 early.org/en Mar 2023
Tau​2 ​ = 0.00, I​2 ​ = 0.0%, p = 0.28
Favors ensitrelvir
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Mukae (DB RCT)
45%
0.55 [0.37-0.81]
viral load
14 (n)
14 (n)
Improvement, RR [CI]
Treatment
Control
Mukae (DB RCT)
32%
0.68 [0.56-0.82]
viral time
113 (n)
108 (n)
Tau​2 ​ = 0.00, I​2 ​ = 0.0%, p < 0.0001
Early treatment
35%
0.65 [0.54-0.77]
0/127
0/122
35% improvement
All studies
35%
0.65 [0.54-0.77]
0/127
0/122
35% improvement
2 ensitrelvir COVID-19 viral clearance results
c19 early.org/en Mar 2023
Tau​2 ​ = 0.00, I​2 ​ = 0.0%, p < 0.0001
Favors ensitrelvir
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Mukae (DB RCT)
45%
0.55 [0.37-0.81]
viral load
14 (n)
14 (n)
Improvement, RR [CI]
Treatment
Control
Mukae (DB RCT)
9%
0.91 [0.76-1.08]
improv.
116 (n)
111 (n)
Tau​2 ​ = 0.10, I​2 ​ = 81.4%, p = 0.21
Early treatment
27%
0.73 [0.45-1.19]
0/130
0/125
27% improvement
All studies
27%
0.73 [0.45-1.19]
0/130
0/125
27% improvement
2 ensitrelvir COVID-19 Randomized Controlled Trials
c19 early.org/en Mar 2023
Tau​2 ​ = 0.10, I​2 ​ = 81.4%, p = 0.21
Effect extraction pre-specified (most serious outcome)
Favors ensitrelvir
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Mukae (DB RCT)
9%
0.91 [0.76-1.08]
improv.
116 (n)
111 (n)
Improvement, RR [CI]
Treatment
Control
Tau​2 ​ = 0.00, I​2 ​ = 0.0%, p = 0.28
Early treatment
9%
0.91 [0.76-1.08]
0/116
0/111
9% improvement
All studies
9%
0.91 [0.76-1.08]
0/116
0/111
9% improvement
1 ensitrelvir COVID-19 peer reviewed studies
c19 early.org/en Mar 2023
Tau​2 ​ = 0.00, I​2 ​ = 0.0%, p = 0.28
Effect extraction pre-specified (most serious outcome)
Favors ensitrelvir
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Mukae (DB RCT)
45%
0.55 [0.37-0.81]
viral load
14 (n)
14 (n)
Improvement, RR [CI]
Treatment
Control
Mukae (DB RCT)
36%
0.64 [0.41-1.00]
viral load
15 (n)
14 (n)
Mukae (DB RCT)
45%
0.55 [0.34-0.90]
viral time
15 (n)
14 (n)
Mukae (DB RCT)
44%
0.56 [0.35-0.92]
viral time
13 (n)
14 (n)
Mukae (DB RCT)
54%
0.46 [0.05-4.38]
viral+
1/12
2/11
Mukae (DB RCT)
-10%
1.10 [0.22-5.51]
viral+
3/15
2/11
Mukae (DB RCT)
80%
0.20 [0.01-3.80]
viral+
0/13
2/13
Mukae (DB RCT)
54%
0.46 [0.05-4.53]
viral+
1/14
2/13
Mukae (DB RCT)
54%
0.46 [0.10-2.12]
viral+
2/14
4/13
Mukae (DB RCT)
90%
0.10 [0.01-0.85]
viral+
0/15
4/13
Mukae (DB RCT)
80%
0.20 [0.05-0.75]
viral+
2/14
10/14
Mukae (DB RCT)
63%
0.37 [0.15-0.92]
viral+
4/15
10/14
Mukae (DB RCT)
9%
0.91 [0.59-1.40]
viral+
10/14
11/14
Mukae (DB RCT)
-10%
1.10 [0.79-1.55]
viral+
13/15
11/14
Mukae (DB RCT)
9%
0.91 [0.76-1.08]
improv.
116 (n)
111 (n)
Mukae (DB RCT)
17%
0.83 [0.69-0.99]
improv.
114 (n)
111 (n)
Mukae (DB RCT)
32%
0.68 [0.56-0.82]
viral time
113 (n)
108 (n)
Mukae (DB RCT)
44%
0.56 [0.42-0.75]
viral time
113 (n)
108 (n)
Ensitrelvir COVID-19 outcomes
c19 early.org/en Mar 2023
Favors ensitrelvir
Favors control
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation.
FLCCC and
WCH
provide treatment protocols.
Thanks for your feedback! Please search before submitting papers and note
that studies are listed under the date they were first available, which may be
the date of an earlier preprint.
Submit